Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Arcturus Therapeutics Holdings (ARCT) Accumulated Depreciation & Amortization (2018 - 2026)

Arcturus Therapeutics Holdings filings provide 8 years of Accumulated Depreciation & Amortization readings, the most recent being $12.5 million for Q4 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization rose 5.76% to $12.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $12.5 million, a 5.76% increase, with the full-year FY2025 number at $12.5 million, up 5.76% from a year prior.
  • Accumulated Depreciation & Amortization hit $12.5 million in Q4 2025 for Arcturus Therapeutics Holdings, up from $12.0 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $13.4 million in Q2 2025 to a low of $3.4 million in Q1 2021.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $7.5 million (2023), compared with a mean of $7.9 million.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: surged 51.47% in 2023 and later rose 5.76% in 2025.
  • Arcturus Therapeutics Holdings' Accumulated Depreciation & Amortization stood at $4.3 million in 2021, then skyrocketed by 35.88% to $5.8 million in 2022, then skyrocketed by 51.13% to $8.7 million in 2023, then surged by 35.14% to $11.8 million in 2024, then rose by 5.76% to $12.5 million in 2025.
  • The last three reported values for Accumulated Depreciation & Amortization were $12.5 million (Q4 2025), $12.0 million (Q3 2025), and $13.4 million (Q2 2025) per Business Quant data.